A Window That May Have Already Closed
A 71-year-old on androgen deprivation therapy who is already noticing the breast changes prophylaxis is meant to prevent — testing what's actually left to offer once the usual window for prevention has arguably passed.
Arthur L. has played golf weekly with the same three friends for over twenty years and was diagnosed with locally advanced prostate cancer two months ago, treated with a GnRH agonist as primary androgen deprivation therapy alongside external beam radiation to the prostate itself. He returns today, six weeks into ADT, having noticed tenderness and a small amount of firm swelling beneath both nipples over the past two weeks — changes he wasn't specifically warned to watch for, and that he mentioned somewhat hesitantly, uncertain whether they were a normal part of treatment or something requiring attention.
Gynecomastia is a well-documented consequence of androgen deprivation therapy, driven by the loss of testosterone's normal restraining effect on breast tissue while estrogen, converted peripherally from residual adrenal androgens, continues acting on the same tissue largely unopposed. Reported incidence with GnRH agonist monotherapy runs meaningfully lower than with older antiandrogen-monotherapy regimens, but is still substantial enough, and bothersome enough to a real fraction of men, that prophylactic strategies have been studied directly rather than left to reactive management alone. The two most established options work through genuinely different mechanisms and, more relevantly to Arthur's case, at genuinely different points in the treatment timeline: low-dose prophylactic radiotherapy to the breast bud, given before or very early in ADT, has real trial evidence reducing gynecomastia incidence, though its effect on breast pain specifically is more modest; tamoxifen, an estrogen-receptor antagonist, has shown stronger comparative effectiveness across published trials for both gynecomastia and breast pain, including some evidence of benefit when started after ADT is already underway rather than purely as upfront prevention.
Arthur's case sits in a genuinely ambiguous window between those two evidence bases: he is six weeks into ADT, past the point radiotherapy's own supporting trials were designed around, but with changes still early and mild rather than established, longstanding gynecomastia. Whether either intervention retains its full preventive value once real, if early, tissue change is already underway — as opposed to purely anticipatory use before any change appears — is not a question either trial base was built to answer directly, since most of the supporting studies enrolled men before ADT started or very early in its course, not at the first sign of symptoms the way Arthur is presenting today.
Oncology follow-up, weighing options against a window that may have narrowed
I want to be honest about what the radiotherapy trials actually tested, because I think it changes how much I'd offer this to him now. The prophylactic breast radiotherapy studies enrolled men before ADT started or very early in its course — genuine prevention, before any tissue change is present. Arthur is six weeks in with real, if early, tenderness and swelling already there. I'm not confident radiotherapy's demonstrated benefit transfers cleanly to a patient who's already past the window those trials were built around.
That's a fair distinction, and it points toward tamoxifen rather than radiotherapy for him specifically. Tamoxifen has stronger comparative trial evidence than radiotherapy for both gynecomastia and breast pain across the published studies, and unlike the radiotherapy trials, some of that evidence includes men started on tamoxifen after ADT was already underway, not purely as upfront prevention. It's a more direct mechanistic fit for where Arthur is right now — blocking estrogen's effect on tissue that's already responding to it, not just trying to prevent that response from ever starting.
I'd frame this less as prophylaxis at this point and more as early treatment of a process that's already begun, which tamoxifen's evidence base actually supports better than radiotherapy's does.
Given he's already symptomatic rather than purely anticipating this, tamoxifen makes practical sense as the better-fitted option for where he actually is in the timeline. I'd start it now, with a follow-up exam in six weeks to confirm the tenderness and swelling are actually improving rather than simply not worsening, and keep radiotherapy on the table only if tamoxifen isn't tolerated or isn't working.
Agreed: tamoxifen started today, reframed explicitly as early treatment of an already-underway process rather than pure prophylaxis, with a follow-up exam in six weeks to confirm real improvement rather than simply the absence of further progression.
The radiation oncologist's honest acknowledgment that his own modality's evidence base doesn't clearly extend to Arthur's specific timing was accepted by the group as decisive, not disputed — the choice of tamoxifen over radiotherapy rested directly on that distinction, not on a general ranking of one treatment as superior to the other.